Taigen Biopharmaceuticals Holdings Ltd operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Taigen Biopharmaceuticals Holdings Ltd with three other
companies in this sector in Taiwan:
Medigen Biotechnology Corporation
sales of 457.78 million Taiwanese Dollars [US$14.82 million]
of which 78%
was Drug Discovery),
Genomics Biosci &Tech Co Ltd
(439.53 million Taiwanese Dollars [US$14.23 million]
Sofiva Genomics Co Ltd
(423.94 million Taiwanese Dollars [US$13.73 million]
Sales increased substantially in 2017:
Taigen Biopharmaceuticals Holdings Ltd reported sales of 553.21 million Taiwanese Dollars (US$17.91 million)
December of 2017.
increase of 278.9%
versus 2016, when the company's sales were 146.02 million Taiwanese Dollars.
Sales of Medical Development saw an increase
318.8% in 2017, from
131.49 million Taiwanese Dollars to 550.66 million Taiwanese Dollars.
Not all segments of Taigen Biopharmaceuticals Holdings Ltd experienced an increase in sales in 2017:
sales of Medical Consultance fell 82.5% to 2.55 million Taiwanese Dollars.